How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Libtayo is given by a doctor or nurse, not picked up at a pharmacy.

What to do

  1. Ask your care team or your plan what you’d pay before your visit.

Your care team and your insurance decide which product you get.

Compare every option

Brand name

Libtayo, the original

Cash priceAsk the pharmacy
Ways to save on Libtayo

The maker’s card

LIBTAYO Surround Commercial Copay Program

Savings card from Regeneron

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a year

The card takes up to $25,000 a year off your co-pay.

Sign up on libtayo.com 

Or call 1-877-542-8296.

In the maker’s words

“You may pay as little as $0 out of pocket for LIBTAYO, up to $25,000 in assistance per year, which includes copay, coinsurance, and deductibles for LIBTAYO product and administration charges.”

From the maker’s offer on libtayo.com, checked November 17, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized generic

There isn’t one.

Not soldThere isn’t one

Regular generic

Libtayo is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

Not soldAsk the pharmacy

What it’s used for

What the FDA label says

LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated:

Cutaneous Squamous Cell Carcinoma (CSCC)

  • for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.
  • for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation.

Basal Cell Carcinoma (BCC)

  • for the treatment of adult patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.

Non-Small Cell Lung Cancer (NSCLC)

  • in combination with platinum‐based chemotherapy for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is:
    • locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or
    • metastatic.
  • as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is:
    • locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or
    • metastatic.

Source: the FDA label for Libtayo (Regeneron Pharmaceuticals, Inc.), August 31, 2026. Full label on DailyMed 

Good to know

  • “Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
  • Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.